Analysis of ARHGAP4 Expression With Colorectal Cancer Clinical Characteristics and Prognosis

Fu, Ming-sheng; Pan, Shuxian; Cai, Xiujun; Yuan-Xin, Hu; Zhang, Weijie; Pan, Qincong

doi:10.3389/fonc.2022.899837

Cited by 9 publications

(8 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previously, ARHGAP4 RNA levels have been found to correlate with survival in CRC presented by The Human Protein Atlas (24). A study published in 2022 using GEPIA consistently found ARHGAP4 expression to correlate with adverse prognosis in CRC (25). A previous study has also found indications that high ARHGAP4 levels by immunohistochemical analysis is an independent predictor for poor prognosis in scirrhous-type gastric cancer (29).…”

Section: Discussionmentioning

confidence: 97%

“…The Human Protein Atlas indicates that mRNA expression levels of ARHGAP4 may influence survival in colorectal cancer (24). A prior study using online Gene Expression Profiling Interactive Analysis (GEPIA) found that high levels of ARHGAP4 expression was correlated with adverse prognosis in CRC (25). So far, there is no report exploring the impact of ARHGAP4 expression on patient outcome in CRLM.…”

mentioning

confidence: 99%

See 1 more Smart Citation

ARHGAP4 as a Prognostic Biomarker for Colon Liver Metastases After Surgical Resection

TORÉN,

SASOR,

ANSARI

et al. 2024

Anticancer Res

View full text Add to dashboard Cite

Background/Aim: To select and stratify patients for optimal treatment plans is challenging. Identification of cancerrelated biomarkers that serve as predictors for prognosis and treatment response is essential to better predict treatment outcome and find future targets for therapy. Previous data has suggested ARHGAP4 as a relevant biomarker in colorectal cancer (CRC) . The purpose of this study was to assess how ARHGAP4 expression affected patients undergoing surgery for colon liver metastasis (CLM) in terms of overall survival (OS). Patients and Methods: A total of 251 patients undergoing resection of CLM from 2006 to 2017 were included. Corresponding resected tumor specimens were examined for ARHGAP4 expression levels by immunohistochemistry (IHC).The correlation between ARHGAP4 expression and postoperative survival was analyzed. Results: High expression levels of ARHGAP4 were seen in 60% of patients. High expression levels of ARHGAP4 were correlated with adverse prognosis after hepatectomy due to CLM. Survival data generated using Cox proportional hazard model showed a statistically significant difference between high and low ARHGAP4 expression groups by univariate (HR=1.5, 95% CI=1.1-2.2) and multivariate (HR=1.5, 95% CI=1.0-2.1) analysis. In multivariate Cox regression, high ARHGAP4 expression, preoperative CEA levels and presence of vascular invasion by pathological examinations were independent predictive factors of overall survival. Conclusion: ARHGAP4 is a novel prognostic biomarker after resection of CLM.

show abstract

Section: Discussionmentioning

confidence: 97%

mentioning

confidence: 99%

ARHGAP4 as a Prognostic Biomarker for Colon Liver Metastases After Surgical Resection

TORÉN,

SASOR,

ANSARI

et al. 2024

Anticancer Res

View full text Add to dashboard Cite

show abstract

“…It has been reported that ARHGAP4 can be a novel regulator of in pancreatic cancer cells [ 34 ]. Moreover, the high expression of ARHGAP4 in colorectal cancer is related to the immune cells such as B cells, CD8 + and CD4 + T cells, macrophages, neutrophils, and dendritic cells [ 35 ]. ARHGAP4 maybe a new target for POR treatment.…”

Section: Discussionmentioning

confidence: 99%

Cai’s prescription inhibits granulosa cell apoptosis through ARHGAP4 on poor ovarian responders

Wang,

Liu,

Nie

et al. 2024

J Ovarian Res

View full text Add to dashboard Cite

Purpose Poor ovarian response (POR) is a big challenge for in vitro fertilization. The traditional Chinese medicine, Cai’s Prescription of Tonifying Kidney and Strengthening Vitals (Cai’s Prescription) has yielded satisfactory results for POR treatment clinically, but systematic scientific research of Cai’s Prescription is not well reported. This study aimed to investigate the clinical effect of Cai’s Prescription on poor ovarian responders and its biological mechanism. Methods Serum was collected from poor ovarian responders, and IL-1β, INFγ, FSH, E2 and AMH levels were analyzed by ELISA. Ovarian antral follicles were identified and counted using transvaginal ultrasound. The embryo quality grading were done on day 3 after retrieval. We used high-throughput sequencing of granulosa cells to investigate the gene transcription patterns of ovarian granulosa cells in poor ovarian responders after Cai’s Prescription pretreatment. The expression level of ARHGAP4 was analyzed by quantitative real-time PCR and western blot. The effects of ARHGAP4 for granulosa cells were analyzed by CCK-8 assay, annexin-V and PI staining, ELISA and western blot. The effects of Cai’s Prescription on the expression of PI3K-Akt pathway and apoptosis were analyzed by western blot. Results In this study, we found that Cai’s Prescription pretreatment had the tendency to improve the ovarian reserve function and could increase the number of high quality embryos for poor ovarian responders. Through high-throughput sequencing of mRNA in granulosa cells, we discovered ARHGAP4, which is a member of GTPase-activating proteins (GAPs) may be a candidate target for POR treatment. ARHGAP4 was significantly increased in poor ovarian responders and can be recovered after Cai’s Prescription pretreatment. Mechanically, combining the cell line model and clinical tissue samples, we found that ARHGAP4 can accelerate cell apoptosis and inflammation response in granulosa cells via PI3K-Akt signaling pathway. In addition, Cai’s Prescription pretreatment for three months significantly reduced the high level of ARHGAP4 in poor ovarian responders. Conclusion This study shows that the traditional Chinese medicine, Cai’s Prescription yielded satisfactory results for poor ovarian responders clinically and ARHGAP4 may be a candidate target for POR treatment.

show abstract

“…However, the specific biomarkers for diagnosis, individualized treatment and predicting prognosis of KIRC are still needed to be evaluated. Some investigations have shown that ARHGAP4 is highly expressed in colorectal cancer, gastric cancer and cervical cancer, and is related to tumor progression and prognosis [30,31,32]. Similarly, the expression of ARHGAP4 has a certain effect on the effect of chemotherapy in ovarian tumors [33].…”

Section: Discussionmentioning

confidence: 99%

Rho GTPase-activating protein 4 is upregulated in Kidney Renal Clear Cell Carcinoma and associated with poor prognosis and immune infiltration

Xiao,

Lv,

Lin

et al. 2024

CBM

View full text Add to dashboard Cite

BACKGROUND: Kidney Renal Clear Cell Carcinoma (KIRC) is a malignant tumor that seriously threatens human health. Rho GTPase-activating protein 4 (ARHGAP4) plays an important role in the occurrence and development of tumors. OBJECTIVE: The purpose of this study was to explore the role of ARHGAP4 in the progression of KIRC and its diagnostic and prognostic value. METHODS: Multiple analytical methods and in vitro cell assays were used to explore the expression of ARHGAP4 and its value in the progression, diagnosis and prognosis of KIRC. The biological function of ARHGAP4 was studied by GO analysis and KEGG pathway analysis, and then the relationship between ARHGAP4 and immune infiltration was analyzed. RESULTS: The expression of ARHGAP4 was significantly up-regulated in KIRC. We found that the high expression of ARHGAP4 was related to the progression of KIRC and suggested a poor prognosis. Compared with normal tissues, ARHGAP4 had a better diagnostic value in KIRC. The biological function of ARHGAP4 was related to immunity, and its expression was also closely related to tumor immune infiltration and immune checkpoints. CONCLUSIONS: Our study demonstrated that ARHGAP4 may be a biomarker, which is related to the progression, diagnosis and prognosis of KIRC. Its biological functions are related to tumor immune infiltration.

show abstract

Analysis of ARHGAP4 Expression With Colorectal Cancer Clinical Characteristics and Prognosis

Cited by 9 publications

References 30 publications

ARHGAP4 as a Prognostic Biomarker for Colon Liver Metastases After Surgical Resection

ARHGAP4 as a Prognostic Biomarker for Colon Liver Metastases After Surgical Resection

Cai’s prescription inhibits granulosa cell apoptosis through ARHGAP4 on poor ovarian responders

Rho GTPase-activating protein 4 is upregulated in Kidney Renal Clear Cell Carcinoma and associated with poor prognosis and immune infiltration

Contact Info

Product

Resources

About